Latest Animal Health News

PGG Wrightson delivered a sharp improvement in FY26 earnings, with Operating EBITDA up 15% to NZ$64.3 million and net profit rising 46% to NZ$15.6 million. The result supports a fully imputed 5.5 cents per share final dividend, although debt and GO-STOCK receivables have also expanded.

A multimillion-dollar, multiyear NIH grant will fund an expanded access program for Neurizon’s investigational NUZ-001, potentially giving up to 200 US patients access to the therapy for as long as 96 weeks. The program is designed to add long-term safety, survival and biomarker data alongside the pivotal HEALEY ALS trial.

Neurizon Therapeutics has completed enrolment in its pivotal HEALEY ALS Platform Trial ahead of schedule, secured critical manufacturing and funding agreements, and reduced its net loss for FY2026 while preparing for topline results in late Q2 2027.

Redox Limited reported a robust FY26 with profit after tax rising 19.2% to $91.9 million on record revenue of $1.33 billion, supported by strong North American growth and improved margins. The company declared a fully franked final dividend of 6.5 cents, bringing total dividends to 13 cents per share.

PGG Wrightson posted a robust FY26 with $1.1 billion revenue and a 46% jump in net profit, driven by strong livestock prices and strategic acquisitions.

Argent BioPharma's licensing partner Splash Beverage Group has launched the US veterinary development program for CannEpil®, targeting companion-animal oncology and chronic pain. Led by industry veteran Dr Hunter Land, the initiative follows a defined FDA regulatory pathway and could broaden CannEpil®’s commercial footprint beyond human neurology.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.

Argent BioPharma has eliminated US$5.5 million in secured debt through a global licensing agreement for its CannEpil® epilepsy therapy, while completing a key acquisition and advancing clinical trials in veterinary therapeutics.

Marlin Global's portfolio delivered a 2.0% gross return in Q2 2026, driven by rebounds in ICON and semiconductor holdings, but lagged a strong US market rally led by AI and chip stocks.

Neurizon Therapeutics has secured a critical five-year supply agreement with Elanco Animal Health for GMP-grade monepantel, underpinning the commercialisation readiness of its lead ALS drug candidate NUZ-001.

Bio-Gene Technology has raised A$3.21 million to complete critical safety studies for its novel insecticide Flavocide and ramp up production of its natural insecticide Qcide, advancing its path to commercialisation in multiple global markets.